Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) – Drugs in Development, 2021

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) – Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 5 and 1 respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System and Gastrointestinal which include indications Breast Cancer, Alzheimer's Disease, Bone Disorders, Colon Cancer, Fibrosis, Glioblastoma Multiforme (GBM), Liver Fibrosis, Multiple Myeloma (Kahler Disease), Non-Small Cell Lung Cancer, Prostate Cancer, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC) and Unspecified Cancer.

The latest report Histone Deacetylase 8 – Drugs in Development, 2021, outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)

– The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

– The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Chengdu Jinrui Foundation Biotechnology Co Ltd

Jubilant Therapeutics Inc

Medibiofarma SL

NatureWise Biotech & Medicals Corp

Oceanyx Pharmaceuticals Inc

Shuttle Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Overview

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Companies Involved in Therapeutics Development

Chengdu Jinrui Foundation Biotechnology Co Ltd

Jubilant Therapeutics Inc

Medibiofarma SL

NatureWise Biotech & Medicals Corp

Oceanyx Pharmaceuticals Inc

Shuttle Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Drug Profiles

JBI-097 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JRF-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

largazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBF-132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBM-BMX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-1161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Dormant Products

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Product Development Milestones

Featured News & Press Releases

Nov 04, 2020: Shuttle Pharmaceuticals awarded a new patent for dual function HDAC molecules for HDAC inhibition and ataxia telangiectasia mutated activation for cancer treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Chengdu Jinrui Foundation Biotechnology Co Ltd, 2021

Pipeline by Jubilant Therapeutics Inc, 2021

Pipeline by Medibiofarma SL, 2021

Pipeline by NatureWise Biotech & Medicals Corp, 2021

Pipeline by Oceanyx Pharmaceuticals Inc, 2021

Pipeline by Shuttle Pharmaceuticals Inc, 2021

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports